Drug review: Ibrutinib
Sign Up to like & getrecommendations! Published in 2020 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.4103/ijmpo.ijmpo_36_20
Abstract: Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium… read more here.
Keywords: review ibrutinib; drug; therapy; drug review ... See more keywords